R Squared Ltd Invests $154,000 in BioAge Labs, Inc. $BIOA

R Squared Ltd bought a new stake in BioAge Labs, Inc. (NASDAQ:BIOA) in the third quarter, according to its most recent Form 13F filing with the SEC. The institutional investor bought 26,159 shares of the company’s stock, valued at approximately $154,000. R Squared Ltd owned 0.07% of BioAge Labs as of its most recent SEC filing.

A number of other hedge funds have also recently added to or reduced their stakes in BIOA. Vanguard Group Inc. increased its position in BioAge Labs by 6.0% during the third quarter. Vanguard Group Inc. now owns 1,651,247 shares of the company’s stock worth $9,709,000 after buying an additional 93,694 shares during the period. Geode Capital Management LLC grew its position in shares of BioAge Labs by 60.8% during the second quarter. Geode Capital Management LLC now owns 453,455 shares of the company’s stock worth $1,873,000 after acquiring an additional 171,426 shares during the last quarter. Marshall Wace LLP increased its holdings in shares of BioAge Labs by 324.7% in the 2nd quarter. Marshall Wace LLP now owns 226,789 shares of the company’s stock valued at $937,000 after acquiring an additional 173,388 shares during the period. Stonepine Capital Management LLC raised its position in BioAge Labs by 202.2% in the 2nd quarter. Stonepine Capital Management LLC now owns 151,085 shares of the company’s stock valued at $624,000 after purchasing an additional 101,085 shares during the last quarter. Finally, Bridgeway Capital Management LLC acquired a new position in BioAge Labs in the second quarter valued at $217,000.

Analyst Upgrades and Downgrades

BIOA has been the topic of several recent research reports. Piper Sandler began coverage on BioAge Labs in a research report on Tuesday, January 27th. They issued an “overweight” rating on the stock. Wall Street Zen upgraded BioAge Labs from a “sell” rating to a “hold” rating in a research note on Tuesday, February 3rd. Oppenheimer assumed coverage on BioAge Labs in a research note on Wednesday, February 25th. They set an “outperform” rating and a $60.00 price target for the company. Morgan Stanley set a $23.00 price objective on shares of BioAge Labs in a research report on Wednesday, February 4th. Finally, Weiss Ratings restated a “sell (d-)” rating on shares of BioAge Labs in a research report on Tuesday, January 27th. Three analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the company’s stock. According to MarketBeat, the stock presently has an average rating of “Moderate Buy” and an average price target of $32.67.

BioAge Labs Price Performance

BioAge Labs stock opened at $22.27 on Monday. The stock’s 50 day moving average price is $18.29 and its 200 day moving average price is $11.00. BioAge Labs, Inc. has a 1-year low of $2.88 and a 1-year high of $24.00. The company has a market cap of $798.49 million, a PE ratio of -14.65 and a beta of 1.42.

Insiders Place Their Bets

In other news, insider Paul D. Rubin sold 7,433 shares of the company’s stock in a transaction on Monday, February 2nd. The shares were sold at an average price of $18.75, for a total transaction of $139,368.75. The transaction was disclosed in a legal filing with the SEC, which can be accessed through the SEC website. Also, CFO Dov A. Md Goldstein sold 27,000 shares of the stock in a transaction dated Tuesday, January 13th. The shares were sold at an average price of $19.70, for a total transaction of $531,900.00. Following the completion of the transaction, the chief financial officer owned 22,408 shares of the company’s stock, valued at $441,437.60. This represents a 54.65% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. In the last ninety days, insiders have sold 354,437 shares of company stock worth $5,813,228. Corporate insiders own 20.82% of the company’s stock.

About BioAge Labs

BioAge Labs (NASDAQ: BIOA) is a clinical-stage biotechnology company focused on discovering and developing therapies that address age-associated diseases. The company leverages its proprietary analytics platform to mine large-scale human biological data for insights into the molecular mechanisms of aging. By targeting fundamental aging pathways, BioAge aims to create interventions that extend healthspan and treat conditions that disproportionately affect older populations.

At the core of BioAge’s operations is its integrated drug discovery platform, which combines human omics datasets, machine learning algorithms and experimental validation to identify novel drug targets.